Anand Rathi has maintained a BUY on Max Healthcare, holding a twelve-month target of Rs 1,220 against a market price of Rs 997, an upside of about 22 percent.

Max Healthcare Institute reported a subdued Q3FY26, with EBITDA growth constrained by seasonal softness, temporary operational disruptions, and pre-commissioning costs linked to capacity expansion.

Divi's Labs and Glenmark shares jumped to 52-week highs and the stocks closed near their highs. On technical charts, both the stocks are looking strong.

Max Healthcare Shares touched 52-week high in today's trading session. Max Healthcare opened the trading session at Rs 1,172 but soon witnessed more than 2 percent surge towards Rs 1,194.

Motilal Oswal’s recent analysis of Max Healthcare Institute Ltd (MAXH) suggests a promising growth trajectory backed by robust revenue generation and strategic expansions across multiple healthcare

Market expert Ashish Chaturvedi has suggested four BUY Calls and no SELL Call for today’s trading session, indicating a bullish outlook for Indian markets.